(NYSE: NVS) Novartis Ag's forecast annual revenue growth rate of -2.45% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 4.25%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 7.51%.
Novartis Ag's revenue in 2023 is $52,323,000,000.On average, 3 Wall Street analysts forecast NVS's revenue for 2023 to be $93,171,149,015,000, with the lowest NVS revenue forecast at $91,274,210,285,000, and the highest NVS revenue forecast at $94,546,833,500,000. On average, 3 Wall Street analysts forecast NVS's revenue for 2024 to be $95,356,844,385,000, with the lowest NVS revenue forecast at $94,016,678,940,000, and the highest NVS revenue forecast at $97,512,920,000,000.
In 2025, NVS is forecast to generate $100,308,996,095,000 in revenue, with the lowest revenue forecast at $99,446,837,175,000 and the highest revenue forecast at $101,105,975,110,000.